跳至主要内容
临床试验/JPRN-UMIN000028030
JPRN-UMIN000028030已完成未知

The prediction using diffusion-weighted MRI of the response evaluation in unresectable pancreatic cancer in patients undergoing neoadjuvant therapy. A pilot study - the response evaluation in unresectable pancreatic cancer in patients undergoing neoadjuvant therapy. A pilot study

Wakayama Medical University0 个研究点目标入组 28 人开始时间: 2017年7月10日最近更新:
适应症

试验速览

阶段
未知
状态
已完成
入组人数
28

研究概览

简要总结

Pre/post-treatment whole tumor ADC value correlated with tumor cell destruction rate among all parameters (R=0.630/0.714, P<0.001/<0.0001). The post-treatment cutoff value of vascular abut site ADC for discriminating between grade<IIb and >=grade IIb was determined as 1.42x10-3 mm2/s and predicts R0 curability. For histological response, the post-treatment whole tumor ADC cutoff value for discriminating between grade<IIb and >= grade IIb was determined as 1.40x10-3 mm2/s.

研究设计

研究类型
Observational

入排标准

年龄范围
20years-old 至 ot applicable(—)
性别
All

入选标准

  • 未提供

排除标准

  • 1. Without severe drug allergy. 2. With history of malignant disease within 5 years. 3. Active stutus of infectious disease. 4. With metal in body which is contraindication for MRI. 5. With claustrophobia. 6. Incapability to collaborate in respiration. 7. The presence of uncontrollable ascites. 8. The presence of uncontrollable DM 9. The presence of uncontrollable CHD, angina, HTN, and arrhythmia. 10. The presence of severe neurological, psychological disease or their history.

研究者

相似试验